Single Center, Randomized, Open-label, Cross-over Study to Investigate the Pharmacokinetics of Two Oral Formulations of Elinzanetant After Single Dosing in Healthy Participants
Overview
- Phase
- Phase 1
- Intervention
- Elinzanetant (BAY3427080) treatment A
- Conditions
- Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
- Sponsor
- Bayer
- Enrollment
- 16
- Locations
- 1
- Primary Endpoint
- AUC of elinzanetant
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
Researchers are looking for a new way to treat women who have symptoms by hormonal changes, like those that happen in women during menopause. These symptoms can include hot flashes, night sweats, and changes in blood pressure. These symptoms are caused by hormonal changes occurring during menopausal transition when women may have also changes in their monthly cycles. The menopausal transition most often begins between ages 45 and 55 and leads to menopause, a point in time 12 months after a woman's last period.
The study drug, elinzanetant, was designed to treat symptoms caused by hormonal changes. Before a new treatment can be approved for people to take, researchers perform clinical trials to better understand how this treatment works and to investigate safety.
The purpose of this study is to assess the blood levels of elinzanetant when given as 2 capsules of dose A (what is intended for further research and future commercialization) and also to compare the blood levels when given as 3 capsules of dose B (what was used for research up to now). Furthermore, researchers want to find out if taking of elinzanetant on two time points leads to differences in blood levels of elinzanetant.
This trial will be performed in healthy women aged 40 to 65 years.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Participant must be 40 to 65 years of age inclusive, at the time of signing the informed consent.
- •Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, blood pressure, pulse rate, 12-lead electrocardiogram, body temperature, and laboratory tests.
- •Non-smoker, at least from 3 months before the screening visit onwards
- •Body weight of at least 50 kg and BMI within the range 18.0 and 30.0 kg/m\*2 (inclusive) at screening.
- •Women of childbearing potential will have to use highly effective non-hormonal contraception when having sexual intercourse with a male partner from signing the informed consent form until 5 days after last dose of the study drug. Acceptable methods of contraception for this study are listed in protocol.
- •Women of non-childbearing potential are not required to use contraception. Non-childbearing potential is defined as
- •Postmenopausal state confirmed by follicle stimulating hormone (FSH) level \>40 U/L, or above reference range from the local laboratory, or
- •Surgically sterilized by bilateral tubal ligation, or bilateral oophorectomy with or without hysterectomy documented by medical report verification
Exclusion Criteria
- •Pregnant or breastfeeding women.
- •Any clinically relevant abnormal findings in medical history and physical examination which in the opinion of the investigators, may put the participant at risk because of her participation in the trial or provide difficulties in interpreting the trial data.
- •History or evidence of any clinically relevant cardiovascular, gastrointestinal, endocrine, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal and/or other clinically relevant disease, as judged by the investigator.
- •Pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study intervention will not be normal.
- •Any medical disorder, condition or history of such that would impair the participant's ability to participate or complete this study in the opinion of the investigator.
- •Known hypersensitivity to the study interventions (active substances, or excipients of the preparations).
- •Known severe allergies e.g., allergies to more than 3 allergens, allergies affecting the lower respiratory tract - allergic asthma, allergies requiring therapy with corticosteroids, urticaria or significant non-allergic drug reactions.
- •Relevant diseases within the last 4 weeks prior to the first study intervention administration.
- •Febrile illness within 4 weeks before first study intervention administration.
- •Regular use of medicines.
Arms & Interventions
Participants receive study medication on time point 1
Participants will receive two single doses of elinzanetant in two different treatments in a randomized sequence (Treatment A, Treatment B).
Intervention: Elinzanetant (BAY3427080) treatment A
Participants receive study medication on time point 1
Participants will receive two single doses of elinzanetant in two different treatments in a randomized sequence (Treatment A, Treatment B).
Intervention: Elinzanetant (BAY3427080) treatment B
Participants receive study medication on time point 2
Participants will receive two single doses of elinzanetant in two different treatments in a randomized sequence (Treatment A, Treatment B).
Intervention: Elinzanetant (BAY3427080) treatment A
Participants receive study medication on time point 2
Participants will receive two single doses of elinzanetant in two different treatments in a randomized sequence (Treatment A, Treatment B).
Intervention: Elinzanetant (BAY3427080) treatment B
Outcomes
Primary Outcomes
AUC of elinzanetant
Time Frame: Period 1: Day 1-9, Day 11, Day 13, Day 15; Period 2: Day 1-7, Day 8 (follow up visit)
AUC: Area under the concentration vs. time curve from zero to infinity after single (first) dose
Cmax of elinzanetant
Time Frame: Period 1: Day 1-9, Day 11, Day 13, Day 15; Period 2: Day 1-7, Day 8 (follow up visit)
Cmax: Maximum observed drug concentration in measured matrix after single dose administration
Secondary Outcomes
- Incidence of treatment-emergent adverse events (TEAEs)(Approximately 2 to 3 months)
- Severity of treatment-emergent adverse events (TEAEs)(Approximately 2 to 3 months)